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1  | INTRODUC TION
In adult mammals, following spinal cord injury (SCI), transected axons 
do not regenerate, resulting in persistent and often severe motor 
and sensory deficits. The absence of regeneration is attributed to 
various factors, in particular to the presence of myelin‐associated 
neurite growth inhibitors such as Nogo‐A in the central nervous 
system environment (CNS)1,2 and/or to the presence of insufficient 
levels of neurotrophic factors, such as BDNF, at the site of injury. In 
recent years, several treatment strategies have emerged, promoting 
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Abstract
In spinal cord injured adult mammals, neutralizing the neurite growth inhibitor 
Nogo‐A with antibodies promotes axonal regeneration and functional recovery, al‐
though axonal regeneration is limited in length. Neurotrophic factors such as BDNF 
stimulate neurite outgrowth and protect axotomized neurons. Can the effects ob‐
tained by neutralizing Nogo‐A, inducing an environment favorable for axonal sprout‐
ing, be strengthened by adding BDNF? A unilateral incomplete hemicord lesion at C7 
level interrupted the main corticospinal component in three groups of adult macaque 
monkeys: control monkeys (n = 6), anti‐Nogo‐A antibody‐treated monkeys (n = 7), and 
anti-Nogo-A	antibody	and	BDNF-treated	monkeys	(n	=	5).	The	functional	recovery	
of manual dexterity was significantly different between the 3 groups of monkeys, 
the	lowest	in	the	control	group.	Whereas	the	anti-Nogo-A	antibody-treated	animals	
returned to manual dexterity performances close to prelesion ones, irrespective of 
lesion size, both the control and the anti‐Nogo‐A/BDNF animals presented a limited 
functional recovery. In the control group, the limited spontaneous functional recov‐
ery depended on lesion size, a dependence absent in the combined treatment group 
(anti‐Nogo‐A antibody and BDNF). The functional recovery in the latter group was 
significantly lower than in anti‐Nogo‐A antibody‐treated monkeys, although the le‐
sion was larger in three out of the five monkeys in the combined treatment group.
K E Y W O R D S
brain‐derived neurotrophic factor, hand, manual dexterity, motor control, Nogo‐A antibody 
therapy, nonhuman primates, spinal cord injury
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regeneration in the CNS, some with promising results. In particu‐
lar, neutralizing Nogo‐A with an antibody has led to an improved 
functional recovery from SCI, as well as to regeneration and com‐
pensatory sprouting of corticospinal (CS) fibers in both rodents and 
monkeys.1,3‐12 However, inhibiting Nogo‐A did not prevent the axo‐
tomized CS neurons to shrink and the extent of the CS fibers re‐
growth remains limited.4,7,13
Neurotrophic factors like BDNF have also been proposed as 
therapeutic agents to promote regeneration inside the CNS, but the 
effects of such treatments remain controversial. Indeed, whereas 
several studies concluded that BNDF delivery protects axotomized 
CNS neurons, promotes sprouting of injured axons, and improves 
functional outcome,14‐23 others reported conflicting results.24‐28 
In addition, in adult rats subjected to SCI a treatment combining 
NT‐3 and anti‐Nogo‐A antibody increased regenerative sprouting 
of CS fibers, whereas the combination of BDNF and anti‐Nogo‐A 
antibody had no effect.28 However, no behavioral outcome was 
assessed in the latter study. Moreover, the combination of BDNF 
and anti‐Nogo‐A antibody has not been tested yet in nonhuman 
primates subjected to cervical cord injury. Therefore, the aim of 
the present study was to investigate, in adult macaque monkeys 
subjected to SCI at cervical level whether the addition of BDNF 
can enhance the extent of functional recovery of manual dexterity 
prompted by anti‐Nogo‐A antibody treatment administered alone 
(see	also	Appendix	S1	for	rationale).	We	compared	three	groups	of	
SCI animals: (a) monkeys treated with a control antibody, (b) mon‐
keys treated with monoclonal anti‐Nogo‐A antibody alone, and 
(c) monkeys treated with BDNF combined with anti‐Nogo‐A anti‐
body. The two first group are derived from previous studies,6‐8,13,29 
whereas	the	third	group	consists	of	5	newly	introduced	monkeys	as	
far as behavior is concerned.
Considering evidence that BDNF promotes the intrinsic ca‐
pability of neuron to sprout (see above) and that anti‐Nogo‐A 
antibody treatment makes the CNS environment permissive for 
neurite outgrowth, our hypothesis is that the combined treatment 
(BDNF and anti‐Nogo‐A antibody) in monkeys may enhance func‐
tional recovery from SCI, as compared to single anti‐Nogo‐A an‐
tibody treatment. In our model of SCI in macaques, anti‐Nogo‐A 
antibody treatment administered alone yielded nearly complete 
functional recovery,6,8 thus preventing to detect an improvement 
of functional recovery if BDNF is added to the treatment (ceiling 
effect). For this reason, in the present study, the strategy was to 
generate larger size SCI in order to produce a more extensive and 
extra deficit of manual dexterity. Then, if BDNF and anti‐Nogo‐A 
antibody combined treatments act in a synergistic manner, then 
one may expect a complete functional recovery of manual dexter‐
ity in spite of a large SCI.
The alternative hypothesis, considering some reported ad‐
verse effects of combining the 2 treatments (see above), is that 
functional recovery from SCI is reduced as compared to single 
anti‐Nogo‐A antibody treatment, especially if the cervical lesion 
is larger than in monkeys treated with anti‐Nogo‐A antibody 
alone.
2  | METHODS
2.1 | Animals origin and identification
The data are derived from experiments carried out on a total of 
eighteen macaque monkeys, in accordance with the Guide for 
Care	and	Use	of	Laboratory	Animals	 (ISBN	0-309-05377-3;	1996),	
and approved by local veterinary authorities, including the ethical 
assessment by the local (cantonal) Survey Committee on Animal 
Experimentation and a final acceptance delivered by the Federal 
Veterinary Office (BVET). The monkeys were either obtained from 
our own colony in our animal facility or were purchased from two 
certified	 suppliers	 (BioPrim,	 31450	 Baziège;	 France,	 and	 Harlan	
Buckshire, USA). During the course of the study, the general health 
condition of the monkeys was assessed by measuring their body 
weight regularly, generally before each daily behavioral session. 
During the span of the experimental period, the animals tended pro‐
gressively to increase their body weight. Moreover, after SCI, the 
monkeys did not turn uncooperative and did not show less motiva‐
tion to perform the behavioral tasks. No signs of epilepsy, aggres‐
sion, or excessive fear with respect to the experimenter and animal 
care taker were observed.
In the present report, each monkeys’ identification code con‐
tains, for sake of clarity, a “C” or an “A” or an “AB” at fourth/fifth digit 
position, indicating whether the monkey was, respectively, control 
antibody‐treated, or anti‐Nogo‐A antibody‐treated, or subjected to 
a combinatory treatment composed of anti‐Nogo‐A antibody as‐
sociated with the neurotrophic factor BDNF. However, during the 
course of the experiments, the animals had different names from 
which the daily experimenters could not infer in which group they 
belonged.
2.2 | Behavioral assessment
At the time of the experiments reported here, all monkeys were 
housed in our animal facility, in rooms of 12 cubic meters, each typi‐
cally containing 2‐4 monkeys free to move in the room and to in‐
teract with each other.a  In the morning, before behavioral testing, 
the animal keeper placed the monkeys in cages used to allow sub‐
sequent transfer to the primate chair (see www.unifr.ch/spccr ). The 
monkeys had free access to water and were not food deprived. The 
rewards obtained during the behavioral tests represented the first 
daily access to food. After the tests, the monkeys received additional 
food (fruits, cereals).
The dexterity of each hand was assessed separately with a finger 
prehension task, specifically our modified Brinkman board quanti‐
tative test.30‐34 The tests were conducted using a Perspex board 
(10	cm	x	20	cm)	containing	50	randomly	distributed	slots,	each	filled	
with a food pellet at the beginning of the test (home designed appa‐
ratus) (Figure 1B, inset). Twenty‐five slots were oriented horizontally 
and	 twenty-five	vertically.	The	dimension	of	 the	 slots	was	15	mm	
long, 8 mm wide, and 6 mm deep. Retrieval of the food pellets was 
normally performed using the precision grip (opposition of thumb 
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and index finger). This manual prehension dexterity task was exe‐
cuted	daily,	alternatively	with	one	and	the	other	hand,	4	to	5	times	
per week for several months before and after the unilateral cervi‐
cal cord lesion. A daily behavioral session typically lasted 60 min‐
utes. The performance of each hand was videotaped. In the present 
study, two parameters were assessed: (a) the retrieval score, that is, 
the number of wells from which the food pellets were successfully 
retrieved and brought to the mouth during the first 30 seconds of 
the test, separately for vertical wells (Figure 1A curves with blue 
diamonds), horizontal wells (Figure 1A curves with pink squares), 
or both cumulated (Figure 1A curves with yellow triangles); (b) the 
contact time (CT), defined as the time of contact (in seconds) be‐
tween the fingers and the pellets, calculated for the first vertical well 
and the first horizontal well targeted by the monkey in a given daily 
session (as reported earlier8). The contact time is comparable to the 
prehension time as introduced by Nishimura et al35 for a different 
F I G U R E  1   Panel A: Two examples of behavioral curves showing the retrieval scores of the hand on the side ipsilateral to the cervical 
cord lesion as a function of the days from lesion (before and after lesion). These data were derived from the modified Brinkman board 
task (number of pellets retrieved in 30 seconds), for two lesioned animals treated with anti‐Nogo‐A antibody/BDNF combination. In these 
graphs, day 0 corresponds to the day when the lesion was performed and is represented by a red vertical dashed line. Under each total 
score of each animal (yellow triangle), the scores for the vertical (blue diamonds) and horizontal (pink squares) slots were plotted separately. 
The two horizontal bars placed on each total score represent the prelesion plateau (red) and the postlesion plateau (yellow), respectively. 
Panel B: Relationship between the extent of hemicord lesion in percent and degree of functional recovery of score in % for the modified 
Brinkman board test for vertically and horizontally oriented slots (blue diamonds for control antibody‐treated monkeys, red squares for anti‐
Nogo‐A antibody‐treated monkeys and yellow triangles for anti‐Nogo‐A antibody/BDNF‐treated monkeys). The monkeys that were already 
published were illustrated with an additional white circle inside their geometrical form. In this graph, one can see the tendency that the anti‐
Nogo‐A antibody‐treated animals recovered better as compared to the other treated animals and independently of the size of the performed 
lesion. On the other hand, the animals that have received either the control antibody or the associated treatment anti‐Nogo‐A antibody/
BDNF recovered less even when the lesion was smaller. A photograph, illustrating the modified Brinkman Board task used to assess manual 
dexterity pre‐ and postlesion, was inserted inside the graph for a better comprehension. In this image, one can see the board comprising 
50	slots	containing	a	food	pellet,	25	oriented	vertically	and	25	horizontally.	The	monkey	grasps	the	pellet	in	the	slots	by	performing	the	
precision	grip	(opposition	of	index	finger	and	thumb).	Panel	C:	Reconstruction	of	the	cervical	cord	lesion	in	the	5	newly	introduced	monkeys	
subjected to the combined treatment
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grasping task. The CT reflects the true capacity of performing the 
precision grip using the index finger and the thumb; it is defined as 
the time separating the first contact of the index finger with the food 
pellet and the final successful grasp of the pellet utilizing pad‐to‐pad 
opposition. As compared to the score, the CT is restricted to manual 
dexterity per se as it does not include the time to transport the pel‐
let to the mouth and the time to bring back the arm to the board to 
catch the next pellet.
After	a	period	ranging	from	1	to	5	months	across	individuals,	cor‐
responding to a phase of initial training,36 the monkeys reached and 
maintained a stable level of performance (prelesion plateau). Once 
reaching this level, they were subjected to the unilateral cervical 
cord lesion. After lesion and in absence of treatment (n = 6 control 
antibody monkeys), there was a dramatic loss of manual dexterity, as 
reflected by a score of zero, followed by a progressive functional re‐
covery up to a variable extent across individuals.6,8,32,33 The duration 
of the functional recovery period ranged from 28 to 76 days across 
individuals (n = 6 control antibody monkeys), after which a stable 
level of recovered performance was reached, corresponding to a 
postlesion plateau (see Ref.37 for the quantitative criterion defining 
the plateau onset). In the anti‐Nogo‐A antibody group, the duration 
of functional recovery ranged from 19 to 43 days whereas in the 
combined	treatment	group	the	range	was	20	to	95	days.
The degree of functional recovery was established by calculat‐
ing the ratio in percent of the average retrieval score at postlesion 
plateau to that observed at prelesion plateau. In addition to the av‐
erage score value, the CT of the first vertical and first horizontal 
slots targeted by monkeys was measured in each daily session at 
prelesion and postlesion plateaux. In order to minimize the impact of 
outliers, the prelesion and postlesion CTs were represented by their 
median value (Figure 2C,D). Considering that a good performance is 
reflected by a short CT, the degree of functional recovery derived 
F I G U R E  2   Relationship between the behavioral parameters score and contact time as function of the estimated volume of the cervical 
cord lesion in mm3. Panels A and B: Relationship between the degree of functional recovery of score (as a percentage) for the modified 
Brinkman board test and the estimated volume of the cervical lesion for (A) vertically and (B) horizontally oriented slots (blue diamonds for 
control antibody‐treated monkeys, red squares for anti‐Nogo‐A antibody‐treated monkeys and yellow triangles for anti‐Nogo‐A antibody/
BDNF‐treated monkeys). Panels C and D: Relationship between the degree of functional recovery of contact time needed for the first 
successful retrieval and the estimated volume of the cervical lesion, for (C) vertically and (D) horizontally oriented slots (blue diamonds for 
control antibody‐treated monkeys, red squares for anti‐Nogo‐A antibody‐treated monkeys and yellow triangles for anti‐Nogo‐A antibody/
BDNF‐treated monkeys). In each panel, the dotted blue line and the black dotted line represent the linear regression line calculated for the 
score or contact time and the estimated volume of the lesion for the group of control antibody‐treated monkeys (blue diamonds) and anti‐
Nogo‐A antibody/BDNF‐treated monkeys (yellow triangles), respectively. In four monkeys (*), the dorsolateral funiculus was not completely 
transected and the monkey Mk‐AK differ from the others because postlesion treatment was delayed by 1 week. See Tables 2 and 3 for 
statistical comparisons between the group of monkeys treated with anti‐Nogo‐A antibody and BDNF versus the other 2 groups of monkeys
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from the CTs was expressed quantitatively as the ratio in percent 
of the prelesion median CT to the postlesion median CT. For mea‐
sures of both degrees of functional recovery, derived from the score 
or the CT, respectively, if the calculated values exceeded 100% (ie, 
postlesion performance was better than prelesion performance), the 
recovery was considered to be complete and therefore expressed 
quantitatively as 100% (though this was rare). The percentage of 
functional recovery was the main parameter used to assess the ef‐
fect of a treatment after SCI (anti‐Nogo‐A antibody alone or com‐
bined anti‐Nogo‐A antibody‐BDNF) in comparison with the control 
antibody‐treated monkeys (Figures 1 and 2).
The overall duration of the experiment was quite variable 
across monkeys, especially the pretraining phase36 and the prele‐
sion phase as well. However, considering the relevant portion of 
the prelesion phase with stable behavior, the duration of recovery, 
and a well‐stabilized postlesion plateau of a few months at least, 
the overall duration of the experiment ranged between about 200 
and	350	days.
2.3 | Surgical procedures
All surgical procedures are the same as previously described6‐8,29,38 
and can be found in the Appendix S1. It includes anesthesia, post‐
surgery care of the animals, procedure to perform the cervical cord 
lesion at C7.
2.4 | Treatments and groups of monkeys
At the end of the surgery during which the cervical cord lesion was 
performed, the tip of one or two catheters were inserted intrathe‐
cally in the vicinity of the lesion site. The other side of the catheters 
was attached to an osmotic pump which could deliver a volume of 
2 mL of control antibody (control group n = 6) or of anti‐Nogo‐A 
antibody (anti‐Nogo‐A group n = 7) or of BDNF and anti‐Nogo‐A 
antibody	(combined	treatment	group	n	=	5).	The	5	monkeys	of	the	
combined treatment group were implanted with two pumps, one 
delivering BDNF (1.4 mg in 4 weeks) and the second pump the anti‐
Nogo‐A antibody (14.8 mg in 4 weeks). Further detail on the treat‐
ment procedures and additional monkeys not included in the present 
analysis can be found in the Appendix S1.
2.5 | Histology
The histological procedures are described in the Appendix S1, in 
particular the method to assess the extent and volume of the spinal 
cord lesion.
2.6 | Statistical analysis
The statistical analysis aimed at comparing the various variables 
reflecting the extent of functional recovery (score or CT) across 
TA B L E  1   List of the new monkeys included in the present study with respect to behavior, with identification code
ID code Mk‐ABMx Mk‐ABMa Mk‐ABB Mk‐ABS Mk‐ABP
Species fasc. fasc. fasc. fasc. fasc.
Sex Male Male Male Male Male
Treatment BNDF	&	hNogo BNDF	&	hNogo BNDF	&	hNogo BNDF	&	hNogo BNDF	&	hNogo
Weight 5.4 3.5 5.3 4.2 4.6
“Experimenter Blind” 
procedure
Yes Yes Yes Yes Yes
Hemisection extent (%) 95 94 83 93 77
Volume of lesion (mm3) 9.55 9.81 2.36 10.37 6.2
Functional recovery (%)
Score (vert) 78 89 84 71 72
Score (horiz) 71 43 100 59 65
Contact time (vert) 72 50 57 53 50
Contact time (horiz) 53 59 72 55 41
Completeness of dlf 
section
Yes Yes Yes Yes Yes
Stock farming BioPrim BioPrim BioPrim Buckshire USA Buckshire USA
Note: At the time of the experiment, monkeys were assigned names that did not allow experimenters to determine whether the animal was infused 
with the control (n = 2 excluded from the analysis) or the anti‐Nogo‐A antibody (n = 2 not considered here) or the anti‐Nogo‐A antibody combined 
with BDNF. New names (codes) were assigned to the monkeys during the writing of the manuscript to improve its readability.
Functional recovery (expressed in % for the behavioral parameter “score”) was assessed here based on the modified Brinkman board task, by compar‐
ing the performance pre‐ and postlesion, as explained in detail in the Materials and Methods section.
Abbreviations: dlf, dorsolateral funiculus; fasc., Macaca fascicularis; hNogo, a monoclonal anti‐Nogo‐A antibody which was raised by immunization 
with the whole Nogo‐A‐specific region of the human Nogo‐A sequence; horiz, horizontal; vert, vertical.
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the three groups of monkeys as a function of the volume of lesion 
(Tables 2 and 3). For the score data, the variables tested were the 
score obtained in the vertical slots (VSc) and the score obtained in 
the horizontal slots (HSc). For the CT, the variables were the recov‐
ery of the median CT in the vertical slots (VCT) and the median CT in 
the horizontal slots (HCT). The statistical analysis was an extension 
of that performed earlier,8 based on the original multivariate non‐
parametric approach proposed by Oja and Randles.39 The statistical 
test was extended for a use with R40 and applied to the present be‐
havioral data with the contribution of the Mathematics Department 
of University of Fribourg.
A first trivariate comparison was performed between the 3 
groups of monkeys, with the hypothesis Ho that there is no differ‐
ence between them (Table 2). Second, a bivariate analysis was con‐
ducted to compare one by one the 3 groups of monkeys, with the 
same hypothesis Ho on all combinations of two groups, comparing 
the newly introduced group anti‐Nogo‐A antibody and BDNF versus 
each of the other two groups (Table 3). For the latter one‐by‐one 
group comparison, when the functional recovery was not depen‐
dent on the lesion volume (not statistically significant correlation), a 
univariate	nonparametric	test	was	applied	(Mann-Whitney	rank-sum	
test; see Table 3). The trivariate analysis was also applied to the data 
displayed in Figure 1, in order to compare the functional recovery 
of total score across the 3 groups of monkeys as a function of lesion 
extent expressed in % (see results below).
3  | RESULTS
3.1 | Cervical cord lesion
The location and extent of the lesion were assessed in each mon‐
key by reconstructing the lesion site from histological sections. 
The cervical lesions in the control antibody monkeys (n = 6) and the 
anti‐Nogo‐A antibody monkeys (n = 7) were all illustrated in a pre‐
vious report8their Fig. 1. From these data, the extent of their lesion 
expressed either in percentage of hemisection or in volume (mm3) 
was derived (see Table 1 in Ref.8) and used in the present study 
(Figures 1 and 2). The cervical lesions in the newly introduced 
group	 of	monkeys	 (n	 =	 5)	 subjected	 to	 the	 combined	 treatment	
(anti‐Nogo‐A antibody and BDNF) are illustrated in Figure 1C, with 
their extent listed in Table 1. The aim to produce larger cervical le‐
sion	in	these	5	combined	treatment	monkeys	was	largely	achieved	
as three of these animals (Mk‐ABMa; Mk‐ABMx, Mk‐ABS) had a 
lesion bigger than all monkeys in the two other groups. The le‐
sion size in the last two combined treatment monkeys (Mk‐ABB 
and Mk‐ABP) overlapped with the other groups (Figures 1B and 
2), although Mk‐ABP still stands among the largest lesions when 
expressed in mm3. The average lesion sizes expressed in % of he‐
misection and in volume were as follows. In the control antibody 
group,	it	was	60.3%	and	2.556	mm3; in the anti‐Nogo‐A antibody 
group 68.3% and 3.479 mm3; and in the anti‐Nogo‐A and BDNF 
group	88.4%	and	7.658	mm3.
3.2 | Postlesion recovery of manual dexterity: total 
score versus hemisection extent in %
The manual dexterity was evaluated pre‐ and postlesion using the 
modified Brinkman board task. The manual dexterity score varied 
in a characteristic way during the time course of the experiment 
(Figure 1A), exhibiting first a learning phase with improving score, 
preceding a prelesion plateau corresponding to a stable refer‐
ence level of manual dexterity performance (Figure 1A; red lines). 
Following this phase of stable performance, a unilateral cervical 
TA B L E  2   Trivariate nonparametric statistical comparison (see 
Freund et al8; Oja and Randall39; Oja40) between the three groups 
of monkeys: (a) control antibody; (b) anti‐Nogo‐A antibody; (c) anti‐
Nogo‐A antibody and BDNF for the lesion volume and every other 
variables (score vertical slots = VSc; score horizontal slots = HSc; 
median CT vertical slots = VCT; median CT horizontal slots = HCT), 
corresponding to the four panels of Figure 2
Volume of lesion (mm3)
Condition P‐value
Recovery of score vertical slots (Figure 2A) .013
Recovery of score horizontal slots (Figure 2B) .007
Recovery of CT vertical slots (Figure 2C) .003
Recovery of CT horizontal slots (Figure 2D) .001
TA B L E  3   One‐by‐one statistical comparisons across the same 
three groups taken two by two (all combinations of group 3 versus 
group 1 or group 3 versus group 2). In case the functional recovery 
in the two groups compared were independent from the volume 
of	lesion,	the	statistical	test	was	univariate	(Mann-Whitney	rank-
sum test), whereas it was a bivariate nonparametric statistical 
test (Freund et al8; Oja40) when one of the group exhibited a 
dependence of the functional recovery with respect to the lesion 
volume
P values
 
Control 
antibody
Anti‐Nogo‐A 
antibody
Anti‐Nogo‐A + BDNF VSc2A 0.032†  0.073* 
Anti‐Nogo‐A + BDNF HSc2B 0.019†  0.073† 
Anti‐Nogo‐A + BDNF VCT2C 0.037†  0.005* 
Anti‐Nogo‐A + BDNF HCT2D 0.028†  0.003* 
Note: See Freund et al8 for comparisons between the control antibody 
and the anti‐Nogo‐A antibody monkey groups (their Table 2), not 
repeated here. The here newly introduced group anti‐Nogo‐A antibody 
and BDNF‐treated monkeys, listed in the leftmost column is compared 
for the same functional recovery parameters (VSc vs VSc, HSc vs HSc, 
VCT vs VCT, HCT vs HCT) with the other two groups of monkeys (mid‐
dle and rightmost columns).
2A, 2B, 2C, 2DRefers to the panels A,B,C, and D of Figure 2.
*Univariate	comparison	(Mann-Whitney	rank-sum	test).	
†Bivariate statistical comparison, as described in Freund et al8 and 
Oja.40 
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cord lesion affected the hand with which the monkey reached the 
highest score (dominant hand: see Ref.34). After the lesion, the score 
fell down drastically reaching zero during several days, before a 
progressive reincrease, corresponding to the functional recovery 
phase (Figure 1A). Finally, the score stabilized again into a postlesion 
plateau, reflecting the final extent of functional recovery of manual 
dexterity (Figure 1A; yellow lines).
To assess how functional recovery is related to the size of the 
lesion, the extent of functional recovery (ratio of postlesion versus 
prelesion total score plateaux in percent) was plotted as a function 
of the extent of the hemisection expressed in percent of the hemi‐
cord injured (Figure 1B; see also Table 1 and Ref.8 for individual 
values). As expected and confirming previous data,6,8 control anti‐
body‐treated monkeys exhibited a spontaneous functional recovery 
of total score somewhat dependent on the lesion extent, with lower 
recovery values for lesion extents larger than 60% than for smaller 
lesions (<60%; blue diamonds in Figure 1B). In the anti‐Nogo‐A an‐
tibody‐treated monkeys (red squares in Figure 1B), the functional 
recovery of total score was more prominent than in control monkeys 
and largely independent of the lesion extent (see however Figure 2 
for correlation statistical analyses). A trivariate nonparametric sta‐
tistical analysis on the data displayed in Figure 1B, as described in 
the methods above, yielded a P value of .022, indicating that the 
three groups of monkeys are significant distinct, with respect to the 
functional recovery of total score versus cervical cord lesion extent.
In the newly introduced group of combined treatment monkeys 
(n	=	5,	yellow	triangles	in	Figure	1B),	there	was	no	apparent	relation‐
ship between the functional recovery of total score and the lesion 
extent (see, however, Figure 2 for correlation statistical analyses). A 
comparison of the 2 groups (anti‐Nogo‐A antibody versus combined 
treatment: red squares vs yellow triangles in Figure 1B) showed a 
nonstatistically significant difference of functional recovery of total 
score	(Mann-Whitney	rank-sum	test	P = .073; see, however, separate 
data for vertical and horizontal slots below in Figure 2 and Tables 2 
and 3).
3.3 | Postlesion recovery of manual dexterity: 
separate scores and CTs for Vertical and Horizontal 
slots versus cervical cord lesion volume in mm3
The movement strategy for picking food pellets out of the horizontal 
and vertical slots differs,8,33 the positioning of the fingers inside the 
horizontal slots requiring a rotation of the wrist, not needed for the 
vertical slots. The impact of a lesion on the capacity to empty hori‐
zontal slots reflects this difference and is often more pronounced 
than that observed for the vertical slots. The behavioral scores for 
the vertical and for the horizontal slots were established separately 
(see blue diamonds and red squares in Figure 1A, respectively). As a 
consequence, the functional recovery in % was computed separately 
for the vertical and horizontal slots (Figure 2).
The measure of the extent of the lesion in percent on a single 
histological section taken at the middle of the lesion only (Figure 1C) 
gives information about the degree of the interruption of pathways 
running along the spinal cord. To also take into account the over‐
all magnitude of tissue damage, the functional recovery of scores 
was plotted as a function of the estimated volume of the lesion in 
mm3, for both slot orientations (Figure 2A,B). Similarly, functional 
recovery of contact time was plotted as a function of the estimated 
volume of the lesion in Figure 2C,D, for the vertical and horizontal 
slots, respectively.
A trivariate nonparametric statistical analysis was performed, as 
explained in the methods, on the data displayed in each of the four 
panels in Figure 2. The results of this trivariate analysis showed that, 
for each of the four functional recovery parameters as a function 
of lesion volume, the three groups of monkeys were significantly 
distinct from each other (Table 2). In other words, the functional re‐
covery of score or CT was significantly different when a control anti‐
body was applied, as compared to administration of the anti‐Nogo‐A 
antibody alone or to administration of the combined treatment (anti‐
Nogo‐A antibody and BDNF).
As previously reported8their	Fig.	5 and as expected, the four panels 
in Figure 2(A‐D) show that the functional recovery in % reflected 
by four distinct parameters are indeed inversely correlated with le‐
sion volume in the control monkeys (blue diamonds and blue dashed 
regression lines in Figure 2). In contrast, the functional recoveries 
in the anti‐Nogo‐A antibody‐treated monkeys were not correlated 
to the lesion volume (Figure 2 red squares; see Ref.8 for negative 
correlation statistical data). As far as the combined treatment group 
is concerned (yellow triangles and black dashed regression lines in 
Figure 2), the functional recovery of vertical score, vertical CT, and 
horizontal CT was not correlated to the lesion volume (R	=	−0.176,	
R = 0.102, R	=	−0.428,	respectively;	all	three	with	a	P	value	>	.05).	
Only the recovery of the horizontal score was related to the lesion 
volume in the combined treatment monkeys (Figure 2B, yellow trian‐
gles; R =	−0.84,	P	<	.05).
Previous data demonstrated that the anti‐Nogo‐A antibody en‐
hanced functional recovery from cervical cord lesion,8 represent‐
ing a strong incentive to initiate clinical trials.41 In other words, the 
functional recovery from cervical cord hemisection was significantly 
better when the anti‐Nogo‐A antibody was delivered as compared to 
a control antibody.6,8 The main aim of the present study was to com‐
pare the anti‐Nogo‐A antibody‐treated monkeys of Freund et al8 with 
the newly introduced combined treatment monkeys (anti‐Nogo‐A 
antibody and BDNF). In panels A, C, and D of Figure 2, as the data 
points (red squares and yellow triangles) were independent of the 
lesion volume, a univariate nonparametric comparison of functional 
recovery was performed (Table 3, p‐values with an asterisk). For both 
vertical CT and horizontal CT (panels C and D in Figure 2: red squares 
versus yellow triangles), there was a statistically significant difference 
of functional recovery between the 2 groups: P	=	.005	and	P = .003, 
respectively. It was only a trend when considering the recovery of 
the vertical score (Figure 2 panel A: red squares vs yellow triangles): 
P = .073. For the data in panel B of Figure 2, as the functional recov‐
ery in the combined treatment group was correlated to the lesion 
volume, a bivariate nonparametric analysis was conducted, showing 
also a trend: P = .073). From these two by two comparisons, it can be 
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concluded that, based on the contact time (CT) data, the functional 
recovery was significantly lower in the combined treatment group as 
compared to the anti‐Nogo‐A antibody‐treated group (Table 3). For 
the functional recovery of score, it was also lower in the combined 
group of monkeys as compared to the anti‐Nogo‐A antibody‐treated 
group, but this was only a trend.
Finally, a statistical comparison was made between the newly 
introduced group of monkeys subjected to the combined treatment 
and the control group of monkeys, for the data displayed in the four 
panels of Figure 2. The p‐values listed in Table 3 (middle column), 
yielded from two by two bivariate nonparametric tests, were all 
statistically significant (P	<	 .05).	 It	 can	be	concluded	 that	 the	 four	
parameters of functional recovery were better in the combined 
treatment group as compared to the control group.
4  | CONCLUSION
The main result of the present study is that the 3 groups of monkeys 
subjected to cervical cord hemisection and the administration of 3 
different treatments significantly differ with respect to their four 
functional recovery parameters plotted as a function of lesion vol‐
umes (Figure 2 and Table 2). The present report is an extension of a 
previous study,8 which demonstrated that an intrathecal treatment 
with the anti‐Nogo‐A antibody led to enhanced functional recov‐
ery of manual dexterity in adult macaques, as compared to control 
antibody‐treated monkeys, following hemisection of the cervical 
spinal	cord.	We	report	here	on	a	newly	 introduced	 third	group	of	
monkeys, treated with a combination of anti‐Nogo‐A antibody and 
BDNF, also after cervical cord hemisection, although somewhat 
bigger than in the previous two groups of monkeys (Figure 2). As 
demonstrated by 3 monkeys with the combined treatment and 
subjected to a large lesion, the addition of BDNF did not compen‐
sate in term of functional recovery for the excess in lesion volume. 
These data in monkeys Mk‐ABMx, Mk‐ABMa, and Mk‐ABS rather 
suggest that the functional recovery was most likely reduced by 
the presence of BDNF, as compared to a single treatment limited 
to anti‐Nogo‐A antibody alone (Figure 2). Such tentative conclusion 
is supported by the monkeys Mk‐ABP and Mk‐ABB, overlapping the 
group of anti‐Nogo‐A antibody‐treated monkeys with respect to le‐
sion volume, showing also a diminished functional recovery as com‐
pared to the latter group (Figure 2). Due to the small sample (two 
overlapping monkeys), the conclusion that BDNF does not provide 
strong synergistic effect when added to the anti‐Nogo‐A antibody 
in order to promote functional recovery after cervical cord lesion 
remains only tentative at that step and would need to be confirmed 
on a larger number of monkeys. On the quantitative point of view 
nevertheless, the counteraction of BDNF does not totally suppress 
the beneficial effect of the anti‐Nogo‐A antibody, as the combined 
treatment group of monkeys still recovered better than the control 
antibody‐treated monkeys (Figure 2; Table 3). Note that one monkey 
of the combined treatment group (Mk‐ABB) exhibited a rather good 
functional recovery, higher than the other four monkeys of the same 
group (Figure 2). Although the limited volume of lesion in Mk‐ABB 
may explain this observation (2.4 mm3 versus > 6 mm3 in the other 
4 monkeys), there is also the suspicion that the lesion may be a bit 
more caudal than the other monkeys. Its scores did not drop all the 
way to zero immediately postlesion and the functional recovery was 
clearly faster (14 days) than in the other animals (20 days in Mk‐ABP; 
26	days	in	Mk-ABS;	47	days	in	Mk-ABMa;	95	days	in	Mk-ABMx).
In conclusion, our findings suggest that adding BDNF did not 
potentiate the effects leading to enhanced functional recovery 
acquired when the anti‐Nogo‐A antibody was given alone. It is un‐
likely that the antibodies and BDNF interacted directly. Rather, 
they may exert independent effects on different parts of the ner‐
vous system. BDNF is known to strongly act on dorsal root ganglia 
and their fibers, pain, or spasticity (even below detection limit) 
could be at the origin of decreased hand function. More gener‐
alized CNS effects are also possible. Thus, the rationale to use a 
more broadly acting neurotrophic factor (BDNF rather than NT‐3) 
did not yield the expected benefit.
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ENDNOTE
a A new Swiss regulation has been introduced in September 2010 request‐
ing	now	a	volume	of	45	cubic	meters	at	least	to	be	given	to	a	group	of	2	to	
5	adult	macaque	monkeys.	
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